Covid19 Clinical Trial
Official title:
Feasibility, Usefulness and Evaluation of a Concentrated Rehabilitation for Patients With Persistent Symptoms Post COVID-19
A large proportion of persons who have had COVID-19 have reported persisted symptoms as fatigue and dyspnea months post infection which affect activities of daily living. The aim of the study is to examine the feasibility and safety of a concentrated rehabilitation program with a mobile application follow-up for persons with persistent symptoms post COVID-19 infection. We will examine recruitment availability, adherence to the program, goal achievement, and resources requirements. Methods: A feasibility study with one group pre-post test design with 10-20 persons between 18-67 years, with persistent symptoms post COVID-19 will be included. The intervention is 3+ 1-2 days concentrated rehabilitation with a mobile application follow-up for 3 months. Following assessments wil be used: Cardiopulmonary exercise testing, lung function, functional performance tests, questionnaires regarding dyspnea, fatigue, anxiety, depression, work-status, health status, sleep behavior, physical activity level. Demographic data before and after the intervention will be presented. Focus group interview will be done with the participants. The interview will be analysed using systematic text condensation.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | December 30, 2023 |
Est. primary completion date | December 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 67 Years |
Eligibility | Inclusion Criteria: - persistent symptoms minimum 2 months post COVID-19 infection - reduced exercise capacity level - symptoms of dyspnea and/or fatigue Exclusion Criteria: - diseases where exercise is contraindicated (e.g. unstable angina pectoris) - drug abuse, severe mental illness where treatment in groups are contraindicated. |
Country | Name | City | State |
---|---|---|---|
Norway | Helse i Hardanger | Øystese | Kvam Herad |
Lead Sponsor | Collaborator |
---|---|
Western Norway University of Applied Sciences | Helse-Bergen HF |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiopulmonary exercise test (CPET) | CPET performed at treadmill | 4 months | |
Primary | Chalder Fatigue Questionnaire (CFQ) | Assessing fatigue | 4 months | |
Secondary | International Physical Activity Questionnaire (IPAQ) | Assessing physical activity | 4 months | |
Secondary | Generalized Anxiety Disorder (GAD-7) | Evaluation of mental disorders | 4 months | |
Secondary | Patient Health Questionnaire (PHQ-9) | Assessing health status | 4 months | |
Secondary | Bergen Insomnia Scale (BIS) | Assessing sleep behavior | 4 months | |
Secondary | Client Satisfaction Questionnaire (CSQ-8) | Assessing client satisfaction with the treatment | 3 months | |
Secondary | Work and Social Adjustment Scale (WSAS) | Assessing ability to work and leisure activities. | 4 months | |
Secondary | The Brief Illness Perception Questionnaire (BIPQ) | Assessing the cognitive and emotional representations of illness. | 4 months | |
Secondary | Modified Medical Research Council Dyspnea Scale (mMRC) | Assessing dyspnea | 4 months | |
Secondary | Dyspnea-12 | Assessing dyspnea | 4 months | |
Secondary | Stair Climbing Test (SCT) | Evaluation of functional exercise capacity | 4 months | |
Secondary | 30 second sit to stand test (30STST) | Evaluation of functional exercise capacity | 4 months | |
Secondary | Spirometry, plethysmography and maximal voluntary ventilation | Evaluation of lung function | 4 months | |
Secondary | Bioimpedance measurement | Assessment of body composition | 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |